Hypermethylation of the LATS1 and LATS2 promoters is observed in 50% of breast cancers (Takahashi et al., 2005), whereas genomic loss of LATS1, LATS2, and NF2 also occurs in TNBC (Figure S6B). Here, LATS2 is linked to breast cancer.